Effective Management of Multiple Sclerosis: Shared Decision-Making with the Patient
January 25, 2019
January 25, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by the Potomac Center for Medical Education.
Supported by educational grants from Biogen and EMD Serono.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is intended for MS specialists, neurologists, PCPs, and other healthcare professionals who manage patients with MS.
Early diagnosis is key to improving outcomes in patients with multiple sclerosis (MS), as treatment initiation early in the disease course can help mitigate symptoms and slow disease progression. Recent advances in the pathophysiology of MS have led to new disease-modifying therapies (DMTs) that have the potential to halt or significantly slow disease progression and provide the first-available treatment for patients with primary progressive MS.
However, clinical uncertainty remains in accurately diagnosing MS and individualizing treatments. These issues can preclude MS patients from reaping the optimal benefits of treatment advances. Patients with MS also report suboptimal levels of shared decision-making, a crucial component in managing MS as a chronic disease.
Upon completion of this activity, participants should be able to:
- Identify key clinical components (physical assessment, medical history, laboratory and neuroimaging parameters) utilized in the differential diagnosis of MS
- Evaluate MRI images in the context of individualized patient symptoms and medical histories to make a differential diagnosis of MS
- Compare the mechanisms of action and clinical efficacy/safety profiles of available and late-stage investigational DMTs for the treatment of MS
- Recognize patient preferences and disease specific factors that influence DMT selection and adherence in individual patients with MS
- Integrate strategies to engage in and promote shared-decision making with MS patients
Suhayl Dhib-Jalbut, MD
Professor and Chairman of Neurology
Ruth Dunietz Kushner and Michael Jay Serwitz Chair in Multiple Sclerosis
Rutgers-New Jersey Medical School and
Robert Wood Johnson Medical School
New Brunswick, NJ
Machteld E. Hillen, MD
Neurology Residency Program Director
Director of the Adult Neurology Clinic
Department of Neurology
Rutgers New Jersey Medical School
Physician Accreditation Statement
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Suhayl Dhib-Jabut, MD
- Consultant/Independent Contractor: Celgene, Novartis
- Grant/Research Support: Biogen, Teva
- Honoraria: Celgene, Novartis
Machteld E. Hillen, MD
- Grant/Research Support: Genentech
Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
- Chad Williamson, MS, MBA, CMPP; Blair St. Amand; Ashley Marostica, RN, MSN, CCM: Nothing to disclose
Disclosure of Unlabeled Use
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.